Is melanotan-2 worth the cancer risk?
If you have any dysplastic nevi or family history of melanoma: no. For everyone else: documented short-term tanning works, libido and appetite effects are real, and the case-report literature on tanning-injection-associated melanoma (Langan 2019 JAMA Dermatol) is small but consistent. A full skin check by a dermatologist before starting is the bar; most users skip it.
Last reviewed · Panya.health editorial
What the case-report literature actually shows
Cardones 2009 in Archives of Dermatology described alpha-MSH-induced eruptive melanocytic nevi: existing moles darkened and new ones appeared after melanotan injection, with histology showing real melanocyte proliferation. Langan 2019 in JAMA Dermatology was a clinical review of melanotan-injection-associated melanoma cases, including patients in their 20s and 30s presenting with melanoma at injection sites or in newly-darkened lesions. The case-report literature is small in absolute terms (~30 published cases as of 2024) but the pattern is consistent: melanotan accelerates melanocyte activity, and in users with dysplastic nevi or genetic predisposition, that activity can include malignant transformation. The community framing of melanotan as 'just stimulating tanning' is mechanistically incomplete.
What's also real, separately from the cancer concern
Melanotan-2 binds both MC1R (melanin) and MC4R (appetite + libido). The libido effect is so consistent that the closely-related compound bremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder. Spontaneous erections are common in male users; some users specifically chase this effect. Appetite suppression is real and short-lived (tolerance develops in 4-8 weeks). Nausea on the first few injections is the most common acute side effect. Blood pressure changes have been reported. The libido + appetite effects are NOT what most users start for, but they're consistent enough that anyone planning a course should expect them.
When the trade is bad
Personal history of any skin cancer (melanoma, basal cell, squamous cell). Family history of melanoma in a first-degree relative. Existing dysplastic nevi (atypical moles) without dermatologist clearance. Fitzpatrick skin type 1 (very pale, freckled, doesn't tan, always burns) because the malignant-transformation case reports are over-represented in this group. Pregnancy and breastfeeding. Active or recent cancer of any type. The framing 'I'll just be careful and watch my moles' is the framing that put the Langan 2019 case-series patients into dermatology clinics with unexpected melanoma diagnoses.
Where Panya stands
Melanotan-2 is documented at panya.health/peptide/melanotan-2 with the case-report literature, mechanism, dosing community practice, and the bright-line dermatology screening requirement before any course. Panya does NOT route to vendors for melanotan-2 anywhere. The page lists community-mentioned suppliers without endorsement. Panya's framing on melanotan is more conservative than for most peptides because the published case-report data is concrete and the user-community pattern of skipping the dermatology pre-screen is well-documented.
Read about this peptide
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.